Efficacy of Regional Citrate Anticoagulation versus SalineFlushingduring Intermittent Hemodialysis on blood circuit clotting prevention;A Randomized Clinical Trial

Phase 3

• Conditions: hypocalcemia hypernatremia metabolic alkalosis cardiac arrhythmia; Regional citrate anticoagulants Saline flushing intermittent hemodialysis

• Registration Number: TCTR20210929007
• Lead Sponsor: Bhumibol Adulyadej Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-09-29
• Study Completion: 2022-03-14
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending (Not yet recruiting)
• Sex: All
• Target Recruitment: 42

Inclusion Criteria

Acute setting ; AKI,ESRD Age > 18 yrs Informed consent Undergoing central venous catheters or AVF/AVG, by prescription HD: Low flux dialyzer BFR 200 ml/min Dialyzate Ca 1.75 mEq/L Duration 4 hr

Exclusion Criteria

1.Patients were treated with antiplatelet,oral anticoagulant therapy or other drugs known to affect coagulation within 7 days 2. Acute liver failure 3. DIC 4. Contraindication to systemic anticoagulation: Abnormal plasma total calcium < 7.0 mg/dL Abnormal plasma total magnesium <1.8 mg/dL Abnormal plasma total sodium >145 mg/dL metabolic alkalosis; serum bicarb > 28 mEq/L Known allergy to citrate Documented arrhythmia

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Dialyzer clots 0,60,120,240 min percent of dialyzer clots

Secondary Outcome Measures

Name	Time	Method
hypocalcemia 0,60,120,240 min incidence of hypocalcemia,hypernatremia 0,60,120,240 min incidence of hypernatremia,metabolic alkalosis 0,60,120,240 min incidence of metabolic alkalosis